{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:33:35Z","timestamp":1791851615811,"version":"4.3.4"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,7,25]],"date-time":"2015-07-25T00:00:00Z","timestamp":1437782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s11904-015-0274-8","type":"journal-article","created":{"date-parts":[[2015,7,24]],"date-time":"2015-07-24T05:50:04Z","timestamp":1437717004000},"page":"353-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Extrahepatic Manifestations of Hepatitis C Infection: Navigating CHASM"],"prefix":"10.1007","volume":"12","author":[{"given":"Amy C.","family":"Sherman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,25]]},"reference":[{"key":"274_CR1","doi-asserted-by":"crossref","unstructured":"Innes HA, McDonald SA, Dillon JF, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 2015. doi: 10.1002\/hep.27766","DOI":"10.1002\/hep.27766"},{"key":"274_CR2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","volume":"9","author":"LI Backus","year":"2011","unstructured":"Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509\u2013516.e1. This paper demonstrated that effective HCV treatment had a significant effect on not just liver related mortality, but upon all cause mortality.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"274_CR3","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ Meer van der","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584\u201393.","journal-title":"JAMA"},{"key":"274_CR4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/hep.1840180205","volume":"18","author":"A Tran","year":"1993","unstructured":"Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993;18:253\u20137.","journal-title":"Hepatology"},{"key":"274_CR5","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/jmv.21269","volume":"80","author":"J Bartolome","year":"2008","unstructured":"Bartolome J, Rodriguez-Inigo E, Quadros P, et al. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. J Med Virol. 2008;80:1588\u201394.","journal-title":"J Med Virol"},{"key":"274_CR6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/thy.2012.0507","volume":"23","author":"JT Blackard","year":"2013","unstructured":"Blackard JT, Kong L, Huber AK, Tomer Y. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid. 2013;23:863\u201370.","journal-title":"Thyroid"},{"key":"274_CR7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4254\/wjh.v7.i3.327","volume":"7","author":"C Ferri","year":"2015","unstructured":"Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin\u2019s lymphoma, and cancer. World J Hepatol. 2015;7:327\u201343.","journal-title":"World J Hepatol"},{"key":"274_CR8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.beem.2009.07.004","volume":"23","author":"Y Tomer","year":"2009","unstructured":"Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab. 2009;23:703\u201312.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"274_CR9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJM199307013290118","volume":"329","author":"SE Wilson","year":"1993","unstructured":"Wilson SE, Lee WM, Murakami C, Weng J, Moninger GA. Mooren\u2019s corneal ulcers and hepatitis C virus infection. N Engl J Med. 1993;329:62.","journal-title":"N Engl J Med"},{"key":"274_CR10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ajo.2007.07.028","volume":"144","author":"C Jacobi","year":"2007","unstructured":"Jacobi C, Wenkel H, Jacobi A, Korn K, Cursiefen C, Kruse FE. Hepatitis C and ocular surface disease. Am J Ophthalmol. 2007;144:705\u201311.","journal-title":"Am J Ophthalmol"},{"key":"274_CR11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/ICO.0b013e318268d6d6","volume":"32","author":"E Heck","year":"2013","unstructured":"Heck E, Dingrando A, Proctor C, Cavanagh HD. Viral HCV RNA reactivity of corneal cells in plasma HCV nucleic acid-positive eye donors. Cornea. 2013;32:506\u20137.","journal-title":"Cornea"},{"key":"274_CR12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MEG.0b013e32835bc2f1","volume":"25","author":"LP Zeni","year":"2013","unstructured":"Zeni LP, Viera PD, Michalczuk MT, Birkhan OA, Vilela MA, Alvares-da-Silva MR. Hepatitis C virus induces abnormalities in surface and intraocular pressure: a comparative study. Eur J Gastroenterol Hepatol. 2013;25:411\u20135.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Suppl 3","key":"274_CR13","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/01.aids.0000192083.41561.00","volume":"19","author":"T Laskus","year":"2005","unstructured":"Laskus T, Radkowski M, Adair DM, Wilkinson J, Scheck AC, Rakela J. Emerging evidence of hepatitis C virus neuroinvasion. AIDS. 2005;19 Suppl 3:S140\u20134.","journal-title":"AIDS"},{"key":"274_CR14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0168-8278(02)00172-1","volume":"37","author":"L Kramer","year":"2002","unstructured":"Kramer L, Bauer E, Funk G, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol. 2002;37:349\u201354.","journal-title":"J Hepatol"},{"key":"274_CR15","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jhep.2004.07.022","volume":"41","author":"K Weissenborn","year":"2004","unstructured":"Weissenborn K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004;41:845\u201351.","journal-title":"J Hepatol"},{"key":"274_CR16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1128\/JVI.76.2.600-608.2002","volume":"76","author":"M Radkowski","year":"2002","unstructured":"Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. 2002;76:600\u20138.","journal-title":"J Virol"},{"key":"274_CR17","doi-asserted-by":"crossref","first-page":"10064","DOI":"10.1128\/JVI.76.19.10064-10068.2002","volume":"76","author":"T Laskus","year":"2002","unstructured":"Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol. 2002;76:10064\u20138.","journal-title":"J Virol"},{"key":"274_CR18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1053\/jlts.2002.36393","volume":"8","author":"HE Vargas","year":"2002","unstructured":"Vargas HE, Laskus T, Radkowski M, et al. Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl. 2002;8:1014\u20139.","journal-title":"Liver Transpl"},{"key":"274_CR19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jmv.1890390203","volume":"39","author":"AH Sherker","year":"1993","unstructured":"Sherker AH, Twu JS, Reyes GR, Robinson WS. Presence of viral replicative intermediates in the liver and serum of patients infected with hepatitis C virus. J Med Virol. 1993;39:91\u20136.","journal-title":"J Med Virol"},{"key":"274_CR20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1086\/519285","volume":"196","author":"S Letendre","year":"2007","unstructured":"Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis. 2007;196:361\u201370. Key paper describing mechanisms on brain dysfunction related to HCV in the HIV-infected patient.","journal-title":"J Infect Dis"},{"key":"274_CR21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s13365-014-0245-7","volume":"20","author":"Z Liu","year":"2014","unstructured":"Liu Z, Zhao F, He JJ. Hepatitis C virus (HCV) interaction with astrocytes: nonproductive infection and induction of IL-18. J Neurovirol. 2014;20:278\u201393.","journal-title":"J Neurovirol"},{"key":"274_CR22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s13365-011-0039-0","volume":"17","author":"AD Paulino","year":"2011","unstructured":"Paulino AD, Ubhi K, Rockenstein E, et al. Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. J Neurovirol. 2011;17:327\u201340.","journal-title":"J Neurovirol"},{"key":"274_CR23","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1212\/NXI.0000000000000027","volume":"1","author":"S Morgello","year":"2014","unstructured":"Morgello S, Murray J, Van Der Elst S, Byrd D. HCV, but not HIV, is a risk factor for cerebral small vessel disease. Neurol Neuroimmunol Neuroinflamm. 2014;1:e27.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"274_CR24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s13365-011-0032-7","volume":"17","author":"TL Jernigan","year":"2011","unstructured":"Jernigan TL, Archibald SL, Fennema-Notestine C, et al. Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011;17:248\u201357.","journal-title":"J Neurovirol"},{"issue":"Pt 3","key":"274_CR25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/brain\/111.3.541","volume":"111","author":"R Nemni","year":"1988","unstructured":"Nemni R, Corbo M, Fazio R, Quattrini A, Comi G, Canal N. Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain. 1988;111(Pt 3):541\u201352.","journal-title":"Brain"},{"key":"274_CR26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/ard.60.3.290","volume":"60","author":"O Lidove","year":"2001","unstructured":"Lidove O, Cacoub P, Maisonobe T, et al. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemia. Ann Rheum Dis. 2001;60:290\u20132.","journal-title":"Ann Rheum Dis"},{"key":"274_CR27","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/hep.23216","volume":"50","author":"JS Bajaj","year":"2009","unstructured":"Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50:2014\u201321.","journal-title":"Hepatology"},{"key":"274_CR28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2012.01.051","volume":"221","author":"LE Adinolfi","year":"2012","unstructured":"Adinolfi LE, Restivo L, Zampino R, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496\u2013502.","journal-title":"Atherosclerosis"},{"key":"274_CR29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","volume":"64","author":"YC Hsu","year":"2015","unstructured":"Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495\u2013503.","journal-title":"Gut"},{"key":"274_CR30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.25508","volume":"55","author":"S Petta","year":"2012","unstructured":"Petta S, Torres D, Fazio G, et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology. 2012;55:1317\u201323. Important study that demonstrates relationship between HCV and atherosclerotic disease.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"274_CR31","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1590-8658(07)80012-0","volume":"39","author":"M Boddi","year":"2007","unstructured":"Boddi M, Abbate R, Chellini B, et al. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis. 2007;39 Suppl 1:S55\u201360.","journal-title":"Dig Liver Dis"},{"key":"274_CR32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijcard.2011.07.016","volume":"164","author":"CP Oliveira","year":"2013","unstructured":"Oliveira CP, Kappel CR, Siqueira ER, et al. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol. 2013;164:221\u20136.","journal-title":"Int J Cardiol"},{"key":"274_CR33","doi-asserted-by":"crossref","unstructured":"Chew KW, Bhattacharya D, McGinnis K, et al. Coronary heart disease risk by Framingham risk score in hepatitis C and HIV\/hepatitis C coinfected persons. AIDS Res Hum Retroviruses 2015. Epub ahead of print","DOI":"10.1089\/aid.2014.0284"},{"key":"274_CR34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/HJR.0b013e328336a150","volume":"17","author":"N Friis-Moller","year":"2010","unstructured":"Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491\u2013501.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"274_CR35","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11892-004-0023-7","volume":"4","author":"G Bahtiyar","year":"2004","unstructured":"Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep. 2004;4:194\u20138.","journal-title":"Curr Diab Rep"},{"key":"274_CR36","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1572-0241.2007.01181.x","volume":"102","author":"JF Huang","year":"2007","unstructured":"Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237\u201343.","journal-title":"Am J Gastroenterol"},{"key":"274_CR37","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/hep.27047","volume":"60","author":"CE Ruhl","year":"2014","unstructured":"Ruhl CE, Menke A, Cowie CC, Everhart JE. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology. 2014;60:1139\u201349.","journal-title":"Hepatology"},{"key":"274_CR38","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/apt.12234","volume":"37","author":"ZM Younossi","year":"2013","unstructured":"Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37:647\u201352.","journal-title":"Aliment Pharmacol Ther"},{"key":"274_CR39","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2012.06.021","volume":"57","author":"A Shlomai","year":"2012","unstructured":"Shlomai A, Rechtman MM, Burdelova EO, et al. The metabolic regulator PGC-1alpha links hepatitis C virus infection to hepatic insulin resistance. J Hepatol. 2012;57:867\u201373.","journal-title":"J Hepatol"},{"key":"274_CR40","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2012.04.036","volume":"57","author":"AF Stattermayer","year":"2012","unstructured":"Stattermayer AF, Rutter K, Beinhardt S, et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol. 2012;57:492\u20138.","journal-title":"J Hepatol"},{"key":"274_CR41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2337\/diacare.29.03.06.dc05-2263","volume":"29","author":"M Skowronski","year":"2006","unstructured":"Skowronski M, Zozulinska D, Juszczyk J, Wierusz-Wysocka B. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care. 2006;29:750. author reply 1.","journal-title":"Diabetes Care"},{"key":"274_CR42","first-page":"e23941","volume":"15","author":"SZ Safi","year":"2015","unstructured":"Safi SZ, Shah H, Siok Yan GO, Qvist R. Insulin resistance provides the connection between hepatitis C virus and diabetes. Hepat Mon. 2015;15:e23941.","journal-title":"Hepat Mon"},{"key":"274_CR43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0140-6736(92)91645-O","volume":"339","author":"J Haddad","year":"1992","unstructured":"Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sj\u00f6gren\u2019s syndrome associated with chronic hepatitis C virus liver disease. Lancet. 1992;339:321\u20133.","journal-title":"Lancet"},{"key":"274_CR44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/1348-0421.12202","volume":"58","author":"Y Wang","year":"2014","unstructured":"Wang Y, Dou H, Liu G, et al. Hepatitis C virus infection and the risk of Sj\u00f6gren or sicca syndrome: a meta-analysis. Microbiol Immunol. 2014;58:675\u201387.","journal-title":"Microbiol Immunol"},{"key":"274_CR45","first-page":"1101","volume":"4","author":"S Vita De","year":"2002","unstructured":"De Vita S, Damato R, De Marchi G, Sacco S, Ferraccioli G. True primary Sj\u00f6gren\u2019s syndrome in a subset of patients with hepatitis C infection: a model linking chronic infection to chronic sialadenitis. Isr Med Assoc J. 2002;4:1101\u20135.","journal-title":"Isr Med Assoc J"},{"key":"274_CR46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.md.0000157397.30055.c9","volume":"84","author":"M Ramos-Casals","year":"2005","unstructured":"Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al. Sj\u00f6gren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore). 2005;84:81\u20139.","journal-title":"Medicine (Baltimore)"},{"key":"274_CR47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.revmed.2004.10.020","volume":"26","author":"V Doffoel-Hantz","year":"2005","unstructured":"Doffoel-Hantz V, Loustaud-Ratti V, Ramos-Casals M, et al. Evolution of Sj\u00f6gren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin. La Revue de medecine interne \/ fondee par la Societe nationale francaise de medecine interne. 2005;26:88\u201394.","journal-title":"La Revue de medecine interne \/ fondee par la Societe nationale francaise de medecine interne"},{"key":"274_CR48","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2141.1994.tb05036.x","volume":"88","author":"C Ferri","year":"1994","unstructured":"Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin\u2019s lymphoma. Br J Haematol. 1994;88:392\u20134.","journal-title":"Br J Haematol"},{"key":"274_CR49","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/infdis\/162.2.569","volume":"162","author":"M Pascual","year":"1990","unstructured":"Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis. 1990;162:569\u201370.","journal-title":"J Infect Dis"},{"key":"274_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.165.1.101","volume":"165","author":"G Monti","year":"2005","unstructured":"Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med. 2005;165:101\u20135.","journal-title":"Arch Intern Med"},{"key":"274_CR51","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","volume":"15","author":"L Dal Maso","year":"2006","unstructured":"Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078\u201385.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"274_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","volume":"347","author":"O Hermine","year":"2002","unstructured":"Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89\u201394.","journal-title":"N Engl J Med"},{"key":"274_CR53","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","volume":"23","author":"D Vallisa","year":"2005","unstructured":"Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin\u2019s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23:468\u201373.","journal-title":"J Clin Oncol"},{"key":"274_CR54","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2014-12-618652","volume":"125","author":"P Sultanik","year":"2015","unstructured":"Sultanik P, Klotz C, Brault P, Pol S, Mallet V. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood. 2015;125:2446\u20137.","journal-title":"Blood"},{"key":"274_CR55","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2010-06-275818","volume":"117","author":"F Marcucci","year":"2011","unstructured":"Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117:1792\u20138.","journal-title":"Blood"},{"key":"274_CR56","doi-asserted-by":"crossref","unstructured":"Nyberg AH, Chung JW, Shi JM, Cheetham TC, Chiang KM, Haque R, Younossi ZM, Nyberg LM. Increased cancer rates in patients with chronic hepatitis C: an analysis of the cancer registry in a large U.S. health maintenance organization. J Hepatol 2015;62(2):S220. doi: 10.1016\/S0168-8278(15)30072-6 .","DOI":"10.1016\/S0168-8278(15)30072-6"},{"key":"274_CR57","doi-asserted-by":"crossref","unstructured":"Allison RD, Tong X, Moorman AC, Ly KN, Rupp L, Xu F, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006\u20132010. J Hepatol. 2015. doi: 10.1016\/j.jhep.2015.04.021 .","DOI":"10.1016\/j.jhep.2015.04.021"},{"key":"274_CR58","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.281.17.1588","volume":"281","author":"A Antonelli","year":"1999","unstructured":"Antonelli A, Ferri C, Fallahi P. Thyroid cancer in patients with hepatitis C infection. JAMA. 1999;281:1588.","journal-title":"JAMA"},{"key":"274_CR59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1034\/j.1600-0676.2001.210506.x","volume":"21","author":"M Montella","year":"2001","unstructured":"Montella M, Crispo A, de Bellis G, et al. HCV and cancer: a case\u2013control study in a high-endemic area. Liver. 2001;21:335\u201341.","journal-title":"Liver"},{"key":"274_CR60","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.297.18.2010","volume":"297","author":"TP Giordano","year":"2007","unstructured":"Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010\u20137.","journal-title":"JAMA"},{"key":"274_CR61","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s10620-015-3521-3","volume":"60","author":"HC Gonzalez","year":"2015","unstructured":"Gonzalez HC, Lamerato L, Rogers CG, Gordon SC. Chronic hepatitis C infection as a risk factor for renal cell carcinoma. Dig Dis Sci. 2015;60:1820\u20134.","journal-title":"Dig Dis Sci"},{"key":"274_CR62","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0272-6386(03)00828-X","volume":"42","author":"CM Meyers","year":"2003","unstructured":"Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631\u201357.","journal-title":"Am J Kidney Dis"},{"key":"274_CR63","first-page":"2065","volume":"27","author":"V Agnello","year":"2000","unstructured":"Agnello V. Therapy for cryoglobulinemia secondary to hepatitis C virus: the need for tailored protocols and multiclinic studies. J Rheumatol. 2000;27:2065\u20137.","journal-title":"J Rheumatol"},{"key":"274_CR64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/hep.1840190407","volume":"19","author":"JM Pawlotsky","year":"1994","unstructured":"Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case\u2013control study. Hepatology. 1994;19:841\u20138.","journal-title":"Hepatology"},{"key":"274_CR65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM199302183280703","volume":"328","author":"RJ Johnson","year":"1993","unstructured":"Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993;328:465\u201370.","journal-title":"N Engl J Med"},{"key":"274_CR66","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/ard.57.12.701","volume":"57","author":"V Agnello","year":"1998","unstructured":"Agnello V. Mixed cryoglobulinaemia after hepatitis C virus: more and less ambiguity. Ann Rheum Dis. 1998;57:701\u20132.","journal-title":"Ann Rheum Dis"},{"key":"274_CR67","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1056\/NEJM199403173301104","volume":"330","author":"R Misiani","year":"1994","unstructured":"Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330:751\u20136.","journal-title":"N Engl J Med"},{"key":"274_CR68","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.V81.5.1132.1132","volume":"81","author":"C Ferri","year":"1993","unstructured":"Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood. 1993;81:1132\u20136.","journal-title":"Blood"},{"key":"274_CR69","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood.V90.10.3865","volume":"90","author":"M Casato","year":"1997","unstructured":"Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood. 1997;90:3865\u201373.","journal-title":"Blood"},{"key":"274_CR70","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","volume":"61","author":"L Gragnani","year":"2015","unstructured":"Gragnani L, Fognani E, Piluso A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015;61:1145\u201353.","journal-title":"Hepatology"},{"key":"274_CR71","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3851\/IMP2684","volume":"19","author":"S Nicola De","year":"2014","unstructured":"De Nicola S, Aghemo A, Campise MR, et al. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. Antivir Ther. 2014;19:527\u201331.","journal-title":"Antivir Ther"},{"key":"274_CR72","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood-2009-11-253948","volume":"116","author":"A Petrarca","year":"2010","unstructured":"Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010;116:335\u201342.","journal-title":"Blood"},{"key":"274_CR73","first-page":"816424","volume":"2015","author":"T Urraro","year":"2015","unstructured":"Urraro T, Gragnani L, Piluso A, et al. Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Rep Immunol. 2015;2015:816424.","journal-title":"Case Rep Immunol"},{"key":"274_CR74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1055\/s-2007-1007142","volume":"18","author":"GH Elder","year":"1998","unstructured":"Elder GH. Porphyria cutanea tarda. Semin Liver Dis. 1998;18:67\u201375.","journal-title":"Semin Liver Dis"},{"key":"274_CR75","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11938-000-0038-3","volume":"3","author":"HL Bonkovsky","year":"2000","unstructured":"Bonkovsky HL, Barnard GF. The porphyrias. Curr Treat Options Gastroenterol. 2000;3:487\u2013500.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"274_CR76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000173696","volume":"218","author":"B Cribier","year":"2009","unstructured":"Cribier B, Chiaverini C, Dali-Youcef N, et al. Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboxylase and mutations of HFE gene. A case\u2013control study. Dermatology. 2009;218:15\u201321.","journal-title":"Dermatology"},{"key":"274_CR77","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0168-8278(03)00346-5","volume":"39","author":"JP Gisbert","year":"2003","unstructured":"Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 2003;39:620\u20137.","journal-title":"J Hepatol"},{"key":"274_CR78","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archderm.1996.03890360029006","volume":"132","author":"WJ O\u2019Connor","year":"1996","unstructured":"O\u2019Connor WJ, Murphy GM, Darby C, et al. Porphyrin abnormalities in acquired immunodeficiency syndrome. Arch Dermatol. 1996;132:1443\u20137.","journal-title":"Arch Dermatol"},{"key":"274_CR79","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7326\/0003-4819-121-4-199408150-00018","volume":"121","author":"LB Siegel","year":"1994","unstructured":"Siegel LB, Eber BB. Porphyria cutanea tarda remission. Ann Intern Med. 1994;121:308\u20139.","journal-title":"Ann Intern Med"},{"key":"274_CR80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0168-8278(95)80438-2","volume":"22","author":"H Takikawa","year":"1995","unstructured":"Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol. 1995;22:249\u201350.","journal-title":"J Hepatol"},{"key":"274_CR81","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/PL00009978","volume":"35","author":"M Furuta","year":"2000","unstructured":"Furuta M, Kaito M, Gabazza E, et al. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol. 2000;35:60\u20132.","journal-title":"J Gastroenterol"},{"key":"274_CR82","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1440-1746.2003.03324.x","volume":"19","author":"Y Nagao","year":"2004","unstructured":"Nagao Y, Sata M. Hepatitis C virus and lichen planus. J Gastroenterol Hepatol. 2004;19:1101\u201313.","journal-title":"J Gastroenterol Hepatol"},{"key":"274_CR83","first-page":"141","volume":"53","author":"M Poljacki","year":"2000","unstructured":"Poljacki M, Gajinov Z, Ivkov M, Matic M, Golusin Z. Skin diseases and hepatitis virus C infection. Med Pregl. 2000;53:141\u20135.","journal-title":"Med Pregl"},{"key":"274_CR84","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jmv.24131","volume":"87","author":"A Lucchese","year":"2015","unstructured":"Lucchese A. A potential peptide pathway from viruses to oral lichen planus. J Med Virol. 2015;87:1060\u20135.","journal-title":"J Med Virol"},{"key":"274_CR85","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000247552","volume":"184","author":"MS Doutre","year":"1992","unstructured":"Doutre MS, Beylot C, Couzigou P, Long P, Royer P, Beylot J. Lichen planus and virus C hepatitis: disappearance of the lichen under interferon alfa therapy. Dermatology. 1992;184:229.","journal-title":"Dermatology"},{"key":"274_CR86","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0016-5085(93)91029-H","volume":"104","author":"U Protzer","year":"1993","unstructured":"Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holtermuller KH. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology. 1993;104:903\u20135.","journal-title":"Gastroenterology"},{"key":"274_CR87","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/0016-5085(93)91099-4","volume":"105","author":"S Boccia","year":"1993","unstructured":"Boccia S, Gamberini S, Dalla Libera M, Strumia R, Venturini D. Lichen planus and interferon therapy for hepatitis C. Gastroenterology. 1993;105:1921\u20132.","journal-title":"Gastroenterology"},{"key":"274_CR88","first-page":"367","volume":"7","author":"T Barreca","year":"1995","unstructured":"Barreca T, Corsini G, Franceschini R, Gambini C, Garibaldi A, Rolandi E. Lichen planus induced by interferon-alpha-2a therapy for chronic active hepatitis C. Eur J Gastroenterol Hepatol. 1995;7:367\u20138.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-015-0274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-015-0274-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-015-0274-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T22:26:18Z","timestamp":1599344778000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-015-0274-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,25]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1007\/s11904-015-0274-8","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,25]]}}}